Zacks Investment ResearchWed, 24 Jun 2026 15:16:07 GMTRVMD Starts Treatment in Phase III Pancreatic Cancer Study on ZoldonrasibRVMD+2.19%
24/7 Wall StreetWed, 24 Jun 2026 11:55:10 GMTAfter Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop WatchingRVMD+2.19%
Seeking AlphaSat, 13 Jun 2026 09:04:54 GMTRevolution Medicines: Strong Data, Big Market (Rating Upgrade)RVMD+2.19%
The Motley FoolThu, 11 Jun 2026 10:45:00 GMTCan Revolution Medicines Be a Game-Changer Stock?RVMD+2.19%
Investors Business DailyMon, 08 Jun 2026 13:06:51 GMTTango Skyrockets 47% On Eye-Popping Pancreatic Cancer ResultsRVMD+2.19%
Zacks Investment ResearchFri, 05 Jun 2026 16:35:45 GMTWhy Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?RVMD+2.19%
Seeking AlphaMon, 01 Jun 2026 16:14:05 GMTRevolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment TranscriptRVMD+2.19%
Zacks Investment ResearchMon, 01 Jun 2026 14:16:24 GMTRVMD Stock Rises on Detailed Results From Pancreatic Cancer StudyRVMD+2.19%
BenzingaTue, 19 May 2026 13:50:31 GMTGraniteShares Files High-Octane 2X ETFs Tied To Nuclear, AI, Biotech Momentum StocksRVMD+2.19%
BenzingaFri, 15 May 2026 15:47:23 GMTCancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: ReportRVMD+2.19%
Zacks Investment ResearchThu, 07 May 2026 17:50:13 GMTRVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense ViewRVMD+2.19%
Seeking AlphaThu, 07 May 2026 09:41:14 GMTRevolution Medicines, Inc. (RVMD) Q1 2026 Earnings Call TranscriptRVMD+2.19%
Investors Business DailyThu, 30 Apr 2026 12:00:48 GMTWhy This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsRVMD+2.19%
WSJTue, 28 Apr 2026 09:30:00 GMTThere's a Revolution in Cancer. But Can Big Pharma Afford It?RVMD+2.19%
The Motley FoolMon, 27 Apr 2026 15:00:00 GMTRevolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It SeemsRVMD+2.19%
BenzingaFri, 17 Apr 2026 11:37:42 GMTTop 2 Health Care Stocks That May Fall Off A Cliff In Q2RVMD+2.19%
ForbesWed, 15 Apr 2026 16:10:15 GMTThis Pill May Help Pancreatic Cancer Patients Live LongerRVMD+2.19%
Seeking AlphaTue, 14 Apr 2026 19:18:01 GMTRevolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions UnderwayRVMD+2.19%
Zacks Investment ResearchTue, 14 Apr 2026 17:35:18 GMTRVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer DataRVMD+2.19%
InvezzMon, 13 Apr 2026 14:13:43 GMTRevolution Medicines surges 38% as pancreatic cancer drug shows breakthroughRVMD+2.19%